17 Grants
2024
Is ERBB4 a Driver of BRAF WT Melanomas?
Riese, David J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R15CA280767-01A1), $450,826USD, 2024-01-01 -- 2026-12-31
2010
Regulation of ErbB4 Signaling by Neuregulin Isoforms
RIESE, DAVID J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA114209-05), $181,463USD, 08/01/2006 -- 08/31/2011
 
Regulation of ErbB4 Signaling by Neuregulin Isoforms
RIESE, DAVID J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 7R01CA114209-06), $57,264USD, 08/01/2006 -- 07/31/2012
2009
Regulation of ErbB4 Signaling by Neuregulin Isoforms
RIESE, DAVID J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA114209-04), $238,664USD, 08/01/2006 -- 07/31/2011
2008
Regulation of ErbB4 Signaling by Neuregulin Isoforms
RIESE, DAVID J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA114209-03), $238,603USD, 08/01/2006 -- 07/31/2011
2007
Regulation of ErbB4 Signaling by Neuregulin Isoforms
RIESE, DAVID J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA114209-02), $238,542USD, 08/01/2006 -- 07/31/2011
2006
R01CA114209 - Regulation of ErbB4 Signaling by Neuregulin Isoforms
Riese, David J
NATIONAL INSTITUTES OF HEALTH (NIH), $800,000, 2006 -- 2011
 
Regulation of ErbB4 Signaling by Neuregulin Isoforms
RIESE, DAVID J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA114209-01A2), $258,732USD, 08/01/2006 -- 07/31/2011
2002
DAMD17-02-1-0130 - Regulation of Prostate Tumor Cell Line Proliferation and Tumorigenicity by ErbB4
Riese, David J
United States Department Of Defense (Dod), $225,000, 2002 -- 2005
 
Tumor Imaging Agents Directed Against ErbB2
RIESE, DAVID J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R21CA089274-02), $150,000USD, 08/23/2001 -- 07/31/2004
2001
R21CA089274 - Tumor Imaging Agents Directed Against ErbB2
Riese, David J
NATIONAL INSTITUTES OF HEALTH (NIH), $200,000, 2001 -- 2003
 
Tumor Imaging Agents Directed Against ErbB2
RIESE, DAVID J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R21CA089274-01A1), $150,000USD, 08/23/2001 -- 07/31/2003
2000
DAMD17-00-1-0415 - Functional analysis of the ErbB4 receptor tyrosine kinase
Riese, David J
United States Department Of Defense (Dod), $130,000, Jul 1, 2000 -- Jun 30, 2004
 
DAMD17-00-1-0416 - Functional analysis of the ErbB4 receptor tyrosine kinase
Riese, David J
United States Department Of Defense (Dod), $210,000, Jul 1, 2000 -- Jun 30, 2003
 
TUMOR CELL LINE PROLIFERATION, MOTILITY AND INVASIVENESS
RIESE, DAVID J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R21CA080770-02), $114,000USD, 04/01/1999 -- 03/31/2001
1999
R21CA80770 - Inhibition of breast tumor cell line proliferation, motility, and invasiveness
Riese, David J
NATIONAL INSTITUTES OF HEALTH (NIH), $150,000, Apr 1, 1999 -- Mar 31, 2001
 
TUMOR CELL LINE PROLIFERATION, MOTILITY AND INVASIVENESS
RIESE, DAVID J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R21CA080770-01), 04/01/1999 -- 03/31/2001